ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Miscellaneous Rheumatic and Inflammatory Diseases"

  • Abstract Number: 031 • 2023 Pediatric Rheumatology Symposium

    Multisystem Inflammatory Syndrome in Children Phenotypes Vary Between SARS-CoV-2 Variants

    Greta Mastrangelo1, Ellen Go2, Paul Tsoukas2, Hua Lu3, Amy Xu2, Arthur Hoi Hin Cheng2 and Rae Yeung4, 1The Hospital of Sick Children,Department of Paediatrics, University of Toronto, Division of Rheumatology, Toronto, ON, Canada, 2The Hospital of Sick Children, Department of Paediatrics, University of Toronto, Division of Rheumatology; Cell Biology Program, The Hospital for Sick Children Research Institute, Toronto, ON, Canada, 3The Hospital for Sick Children, Toronto, ON, Canada, 4The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada

    Background/Purpose: Multisystem Inflammatory Syndrome in Children (MIS-C) is a serious complication associated with COVID-19, presenting as a hyperinflammatory disorder characterized by fever and multiorgan dysfunction.…
  • Abstract Number: 033 • 2023 Pediatric Rheumatology Symposium

    Kawasaki Disease (KD) Criteria Fulfillment and Associated Outcomes in Multisystem Inflammatory Syndrome in Children (MIS-C)

    Lyndsey Cole, Marsha Anderson, Heather Heizer, Michelle Hite, Christina Osborne, Samuel Dominguez and Pei-Ni Jone, University of Colorado School of Medicine, Denver, CO

    Background/Purpose: Multisystem inflammatory syndrome in children (MIS-C) is a hyperinflammatory illness associated with SARS-CoV-2 infection and has overlapping features with Kawasaki Disease (KD). The objective…
  • Abstract Number: 061 • 2023 Pediatric Rheumatology Symposium

    Variation in Treatment Approaches to IVIG- Refractory Kawasaki Disease (KD) Among Pediatric Rheumatologists: The Childhood Arthritis and Rheumatology Research Alliance (CARRA) Treatment of Refractory KD Survey

    Daniel Ibanez1, Bianca Lang2, Ali Yalcindag3, Linda Wagner-Weiner4, Julia Shalen5, Kenneth Schikler6, Shoghik Akoghlanian7, Hulya Bukulmez8, Kristen Hayward9, Sivia Lapidus10, Andrea Ramirez11, Robert Sundel1, Cagri Yildirim-Toruner12 and CARRA Registry Investigators13, 1Boston Children's Hospital, Boston, MA, 2Dalhousie University - Halifax, Halifax, NS, Canada, 3Hasbro Children's Hospital, Milton, MA, 4The University of Chicago, Chicago, IL, 5Johns Hopkins University, Baltimore, MD, 6University of Louisville School of Medicine Norton Children's Hospital, Louisville, KY, 7Nationwide Children's Hospital, Columbus, OH, 8MetroHealth Medical Center, Case Western Reserve, Cleveland, OH, 9Seattle Children's Hospital/University of Washington School of Medicine, Seattle, WA, 10Department of Pediatrics, Joseph M. Sanzari Children's Hospital, Hackensack University Medical Center, Hackensack, NJ, 11Baylor College of Medicine, Houston, TX, 12Baylor College of Medicine, Texas Children's Hospital, Houston, TX, 13CARRA, Washington, DC

    Background/Purpose: Kawasaki disease (KD) is the leading cause of acquired heart disease in children in North America. Initial treatment with IVIG has significantly reduced the…
  • Abstract Number: 080 • 2023 Pediatric Rheumatology Symposium

    Analysis of Proteasomal Activity – a Potential Diagnostic Tool for Proteasome-associated Autoinflammatory Syndromes (PRAAS)

    Yoel Levinsky1, Oded Scheuerman2, Rotem Tal3, Gil Amarilyo3 and Liora Harel3, 1Schneider Children's Medical Center of Israel, Tel Aviv University, Petach Tikva, Israel, 2Pediatric B department, Schneider children's medical center of Israel, Petach Tikva, Israel, 3Pediatric rheumatology clinic, Schneider children's medical center of Israel, Petach Tikva, Israel

    Background/Purpose: Interferonopathies are a recently recognized group of genetic syndromes associated with uncontrolled activation of interferon. PRAAS (proteasome-associated autoinflammatory syndromes) is an interferonopathy caused by…
  • Abstract Number: 117 • 2023 Pediatric Rheumatology Symposium

    A Descriptive Study of Patients with Multisystem Inflammatory Syndrome in Children

    Alexis Begezda, Penn State, State College, PA

    Background/Purpose: Children with childhood-onset systemic lupus erythematosus (cSLE) experience more severe disease than their adult counterparts, in addition to high rates of clinical depressive symptoms…
  • Abstract Number: 134 • 2023 Pediatric Rheumatology Symposium

    Patient-Provider Communication in Pediatric Rheumatology

    Julie Samuels, Emma Wojtal and Rebecca Trachtman, Icahn School of Medicine at Mount Sinai, New York, NY

    Background/Purpose: Communication is an essential part of medical care, especially in Pediatric Rheumatology where children have varying complex chronic diseases. However, there is paucity of…
  • Abstract Number: 0130 • ACR Convergence 2022

    Three Chinese Pedigrees of A20 Haploinsufficiency

    Yi Tian1, Min Shen2, Bingxuan Wu2, linyi Peng2 and Jian Wang3, 1Rheumatology Department, The Second Affiliated Hospital of Dalian Medical University, Dalian, China, 2Department of Rheumatology, Peking Union Medical College Hospital, Beijing, China, 3Jinzhou City Center for Disease Control and Prevention, Jinzhou, China

    Background/Purpose: Haploinsufficiency of A20 (HA20) is a newly described rare autoinflammatory disease caused by TNFAIP3 gene mutations. HA20 has been seldom documented in the Chinese…
  • Abstract Number: 1751 • ACR Convergence 2022

    Diagnosing the Cardiovascular Risk of VIOXX: A Place for Rofecoxib in Pain Management

    Judith Boice, Mark Corrigan and Bradford Sippy, Tremeau Pharmaceuticals, Inc, Concord, MA

    Background/Purpose: Traditional NSAIDs (tNSAIDs) are effective in treating arthritis pain but can be limited by GI adverse events and general bleeding related to platelet inhibition.…
  • Abstract Number: 0131 • ACR Convergence 2022

    Racial Differences in Bone Health of Sarcoidosis Patients: A Retrospective Study

    Emily Peninger1, Christian Ascoli2, Rachel Lane2, Subash Kukreja2, Robert Baughman3 and Nadera Sweiss2, 1University of Chicago, Chicago, IL, 2University of Illinois at Chicago, Chicago, IL, 3University of Cincinnati, Cincinnati, OH

    Background/Purpose: Bone health in sarcoidosis is a complex topic, though data regarding racial differences in this population is lacking. Our study sought to identify racial…
  • Abstract Number: 1844 • ACR Convergence 2022

    Biological Therapy in Neurosarcoidosis: Study of 30 Patients from a Series of 234 Systemic Sarcoidosis from a University Hospital

    Alba Herrero-Morant1, David Martínez-López2, Lara Sánchez-Bilbao2, iñigo Gonzalez-Mazon2, José Luis Martín-Varillas3, Raúl fernández-ramón2, Carmen Alvarez Reguera2, Miguel Ángel González-Gay4 and Ricardo Blanco5, 1Hospital Universitario Marqués de Valdecilla, Ontinyent, Spain, 2Hospital Universitario Marqués de Valdecilla, Santander, Spain, 3Hospital de Laredo, Laredo, Cantabria, Spain, 4Department of Medicine and Psychiatry, Universidad de Cantabria; Rheumatology Division, Hospital Universitario Marqués de Valdecilla; Research group on genetic epidemiology and atherosclerosis in systemic diseases and in metabolic diseases of the musculoskeletal system, IDIVAL, Santander, Spain. Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa, 5Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain

    Background/Purpose: Neurosarcoidosis (NS) is a severe complication of sarcoidosis. NS may be classified according to several subtypes. Data on therapy, including biological therapy (BT) is…
  • Abstract Number: 0133 • ACR Convergence 2022

    Retention Rate of Targeted Therapies in Erdheim-Chester Disease

    Corrado Campochiaro1, alessandro tomelleri1, Francesco Pegoraro2, Giovanni Galardi3, Nicola Farina4, Martina Mazzariol5, Francesco Catamerò6, Giacomo De Luca4, Giulio Cavalli4, Augusto Vaglio7 and Lorenzo Dagna8, 1IRCCS San Raffaele Hospital. Vita-Salute San Raffaele University, Milano, Italy, 2Department of Health Sciences, University of Florence, Firenze, Italy, 3Department of Health Sciences, University of Florence, Florence, Italy, 4IRCCS San Raffaele Hospital - Vita-Salute San Raffaele University, Milano, Italy, 5University of Turin, Torino, Italy, 6Vita-Salute San Raffaele University, Milano, Italy, 7Azienda Ospedaliero Universitaria Meyer, Parna, Italy, 8IRCCS San Raffaele Hospital and Vita-Salute San Raffaele University, Milano, Italy

    Background/Purpose: Erdheim-Chester disease (ECD) is a rare non-Langerhans histiocytosis with a broad clinical spectrum. The therapeutic landscape of ECD has remarkably changed over the last…
  • Abstract Number: 1845 • ACR Convergence 2022

    Mortality Prognostic Factors of Critically Ill Patients with Systemic Autoimmune Diseases Admitted in a Medical Intensive Care Unit: A 20-year Cohort Study

    Pamela Doti1, Ana Luisa Cunha2, Armin Quispe Cornejo3, Ángela Nieto González1, Andre Matos1, Pedro Guevara Hernández1, Pedro Castro Rebollo1 and Gerard Espinosa Garriga1, 1Hospital Clínic, Barcelona, Spain, 2Hospital Senhora da Oliveira, Guimarães, Porto, Portugal, 3Erasme Hospital, Brussels, Belgium

    Background/Purpose: To describe the clinical characteristics of a 20-year cohort of patients with systemic autoimmune diseases (SAD) admitted to a medical intensive care unit (ICU)…
  • Abstract Number: 0136 • ACR Convergence 2022

    Sarcoidosis Incidence After mTOR Inhibitor Treatment

    Matthew Baker1, Emese Vágó2, Yuhan Liu1, Rong Lu1, Suzanne Tamang3, Erzsébet Horváth-Puhó2 and Henrik Sørensen2, 1Stanford University, Stanford, CA, 2Aarhus University Hospital, Aarhus, Denmark, 3Stanford Center for Population Health Sciences, Redwood City, CA

    Background/Purpose: Mechanistic target of rapamycin (mTOR) inhibitors are effective in animal models of granulomatous disease, but their benefit in patients with sarcoidosis is unknown. We…
  • Abstract Number: 1925 • ACR Convergence 2022

    Characterizing Phenotypic Changes by SARS-CoV-2 Variant in Multisystem Inflammatory Syndrome in Children (MIS-C): A Single Institution Case Series

    Sandy D. Hong1 and Emma Leisinger2, 1University of Iowa Stead Family Children's Hospital, Iowa City, IA, 2University of Iowa, Iowa City, IA

    Background/Purpose: Multisystem inflammatory syndrome in children (MIS-C) is a severe hyper-inflammatory condition associated with a recent SARS-CoV-2 infection. Case reports began in April of 2020…
  • Abstract Number: 0507 • ACR Convergence 2022

    Gut Microbe Metabolite Short-Chain Fatty Acids May Associate with Development of Respiratory Involvement in Patients with Relapsing Polychondritis

    Jun Shimizu1, Masanori Murayama2, Yoshishige Miyabe1 and Noboru Suzuki3, 1St. Marianna University School of Medicine, Kawasaki, Japan, 2Kansai Medical University, Hirakata, Japan, 3St. Marianna University School of Medicine, Kawasaki Kanagawa, Japan

    Background/Purpose: Relapsing polychondritis (RP) is an inflammatory disease that affects cartilaginous tissues of the body and the clinical manifestations and disease courses vary considerably among…
  • « Previous Page
  • 1
  • …
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology